Syra Health stock hits 52-week low at $0.12 amid sharp decline

Published 16/04/2025, 17:38
Syra Health stock hits 52-week low at $0.12 amid sharp decline

Syra Health Inc. (SYRA) shares tumbled to $0.11, near its 52-week low of $0.13, reflecting a stark downturn for the healthcare company with a market capitalization now at just $3.55 million. According to InvestingPro analysis, the stock appears undervalued at current levels. The stock’s latest price level underscores a significant retreat from its previous positions, as investors grapple with the challenges facing the firm. Despite showing strong revenue growth of 44.7% and maintaining a healthy current ratio of 5.46, Syra Health has experienced a precipitous drop in its stock value, with a 1-year decline of -83.35%. This sharp decrease has raised concerns among shareholders and market analysts alike, as they assess the company’s performance and future prospects in an increasingly competitive healthcare sector. InvestingPro subscribers can access 12 additional key insights and a comprehensive Pro Research Report for deeper analysis of SYRA’s financial health and growth prospects.

In other recent news, Syra Health Corp. reported a 45% increase in total revenue for 2024, reaching $8 million, with Q4 2024 revenue alone growing by 14% year-over-year to $2 million. Despite the revenue growth, the company faced a net loss of $3.7 million for the year, although this was an improvement from the previous year’s loss of $2.9 million. Furthermore, Syra Health announced a $660,000 contract extension for Population Health with a national healthcare organization, bringing the total contract value to $1.32 million over two years. In a strategic move, Syra Health also decided to voluntarily delist its common stock from the Nasdaq Capital Market, planning to file a Form 25 with the SEC by April 2025. The company expects its stock to be quoted on the OTC market following the delisting. Additionally, Andrew Dahlem has been appointed as the new Chairman of the Board, a change formalized in a recent SEC filing. These developments reflect Syra Health’s ongoing efforts to enhance its business operations and governance structure.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.